{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 460019355
| IUPAC_name = (2''S'')-2-(carbamoylamino)pentanedioic acid
| image = Carglumic acid.svg
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|CDI|carglumic_acid}}
| licence_EU = Carbaglu
| pregnancy_category = unknown
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 30%
| protein_bound = Undetermined
| metabolism = Partial
| elimination_half-life = 4.3 to 9.5 hours
| excretion = Fecal (60%) and [[Kidney|renal]] (9%, unchanged)
<!-- Identifiers -->
| index_label =
| index2_label =
| IUPHAR_ligand = 7458
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 1188-38-1
| ATC_prefix = A16
| ATC_suffix = AA05
| PubChem = 121396
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 1265942
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06775
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 71028
| ChemSpiderID2_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID2 = 108351
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 5L0HB4V1EW
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07130
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201780
<!--Chemical data-->
| C=6 | H=10 | N=2 | O=5
| molecular_weight = 190.2 g/mol
| smiles = C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LCQLHJZYVOQKHU-VKHMYHEASA-N
| synonyms = (''S'')-2-ureidopentanedioic acid
}}

'''Carglumic acid''' is an [[orphan drug]], marketed by Orphan Europe under the trade name '''Carbaglu'''.  Carglumic acid is used for the treatment of [[hyperammonaemia]] in patients with [[N-acetylglutamate synthase|''N''-acetylglutamate synthase]] deficiency.<ref>{{cite journal | vauthors = Caldovic L, Morizono H, Daikhin Y, Nissim I, McCarter RJ, Yudkoff M, Tuchman M | title = Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate | journal = J Pediatr | volume = 145 | issue = 4 | pages = 552–4 | year = 2004 | pmid = 15480384 | doi = 10.1016/j.jpeds.2004.06.047}}</ref><ref>{{cite journal | vauthors = Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C | title = N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy | journal = Ann Neurol | volume = 52 | issue = 6 | pages = 845–9 | year = 2002 | pmid = 12447942 | doi = 10.1002/ana.10406}}</ref> The initial daily dose ranges from 100 to 250&nbsp;mg/kg, adjusted thereafter to maintain normal plasma levels of ammonia.

The US FDA approved it for treatment of hyperammonaemia on March 18, 2010.  Orphan Drug exclusivity expires on March 18, 2017.<ref>{{cite web |url=http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=022562&Product_No=001&table1=OB_Rx |title=Patent and Exclusivity Search Results |format= |work= |accessdate=}}</ref>

== Adverse effects ==
The most common adverse effects include vomiting, abdominal pain, fever, and [[tonsillitis]].<ref>[[Drugs.com]]: {{Drugs.com|ppa|carglumic-acid}} for Carglumic Acid.</ref>

== References ==
{{Reflist}}

{{Other alimentary tract and metabolism products}}

[[Category:Orphan drugs]]
[[Category:Carbamates]]
[[Category:Dicarboxylic acids]]
[[Category:Amino acid derivatives]]